GlassScriptPhysician profile
Alan B Kadet
NPI 1003917980
$4,478.78
in general payments reported to CMS, 2019-2025
30 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $656 · 2021: $685 · 2022: $573 · 2023: $682 · 2024: $612 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $709.76 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $501.00 | 2019-2025 | Breztri, Airsupra |
| Lundbeck LLC | $356.14 | 2022-2025 | Rexulti |
| Allergan, INC. | $327.99 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $309.70 | 2022-2025 | Quviviq, Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $278.13 | 2019-2025 | Trintellix |
| Amgen INC. | $213.02 | 2019-2023 | Otezla, Repatha |
| Gilead Sciences, INC. | $122.46 | 2019 | |
| Amarin Pharma, INC. | $122.07 | 2019-2020 | |
| Genentech USA, INC. | $86.64 | 2020-2022 | |
| Lilly USA, LLC | $81.90 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $74.94 | 2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $62.68 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $60.38 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $43.11 | 2021 | |
| Pfizer INC. | $40.28 | 2020-2025 | |
| Shire North American Group INC | $36.52 | 2019 | |
| Axsome Therapeutics, INC. | $34.79 | 2022 | |
| Almatica Pharma LLC | $34.68 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Sanofi Pasteur INC. | $27.30 | 2019 | |
| Dermira, INC. | $22.18 | 2019 | |
| Novo Nordisk INC | $21.69 | 2024 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $20.01 | 2024 | Voquezna |
| Hikma Pharmaceuticals USA | $19.63 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.99 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.37 | 2022 | |
| Metuchen Pharmaceuticals | $14.59 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.20 | 2024 | Rexulti |
| Horizon Therapeutics Plc | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kadet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.